Rigel Pharmaceuticals (RIGL) Operating Expenses (2010 - 2026)

Rigel Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $46.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 15.71% year-over-year to $46.9 million; the trailing twelve-month figure through Mar 2026 stood at $175.2 million (up 10.08% YoY), and the FY2025 full-year result was $168.8 million, up 8.85% from the prior year.
• Operating Expenses for Q1 2026 stood at $46.9 million, up from $46.6 million in the prior quarter.
• The five-year high for Operating Expenses was $49.2 million in Q4 2022, with the low at $32.2 million in Q2 2023.
• Average Operating Expenses over 5 years is $40.2 million, with a median of $40.8 million recorded in 2022.
• Year-over-year, Operating Expenses sank 31.25% in 2023 and rose 26.54% in 2024.
• Tracing RIGL's Operating Expenses over 5 years: stood at $49.2 million in 2022, then slumped by 31.25% to $33.8 million in 2023, then climbed by 21.03% to $40.9 million in 2024, then advanced by 13.9% to $46.6 million in 2025, then advanced by 0.65% to $46.9 million in 2026.
• The last three Operating Expenses figures came in at $46.9 million (Q1 2026), $46.6 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.

Peer Comparison